TCM Biotech International Corp. (TPE:4169)

Taiwan · Delayed Price · Currency is TWD

280.50

+25.50 (10.00%)

Jul 21, 2026, 1:30 PM CST

354.62% (1Y)

Market Cap	15.06B +313.3%
Revenue (ttm)	703.09M +7.0%
Net Income	-13.80M
EPS	-0.24
Shares Out	59.05M
PE Ratio	n/a
Forward PE	283.33
Dividend	0.36 (0.14%)
Ex-Dividend Date	Jul 20, 2026

Volume	577,685
Open	270.00
Previous Close	255.00
Day's Range	263.00 - 280.50
52-Week Range	60.00 - 288.00
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 4169

Full Company Profile

Financial Performance

In 2025, TCM Biotech International's revenue was 685.49 million, an increase of 2.84% compared to the previous year's 666.53 million. Earnings were 19.17 million, a decrease of -8.76%.

Financial Statements